

I HAVE PLANS.

**AND I
WANT
TO KEEP
THEM**

Understanding your
diagnosis and what's next
with a **ZIIHERA** treatment plan.



AI-generated
synthetic performer;
not a real patient.

What is ZIIHERA?

ZIIHERA (zanidatamab-hrii) 50 mg/mL is a prescription medicine used to treat adults with gastroesophageal cancer (GEA) including gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer. ZIIHERA is used in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr as the first treatment when your GEA:

- cannot be removed by surgery or has spread to other parts of your body (metastatic); **and**
- your tumor tests positive for human epidermal growth factor receptor 2 (HER2 IHC 3+ or IHC 2+/ISH+).

Your healthcare provider will perform a test to make sure ZIIHERA is right for you.

It is not known if ZIIHERA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

ZIIHERA can cause serious side effects, including:

- **Diarrhea.** Diarrhea during treatment with ZIIHERA can be severe, life threatening, and can lead to death. Diarrhea may cause loss of fluids and body salts (electrolytes). To help prevent or reduce diarrhea during treatment with ZIIHERA, your healthcare provider:
 - will tell you to drink more fluids.
 - start you on an antidiarrheal medicine such as loperamide or other treatment, as needed.
 - may temporarily stop, reduce your dose or permanently stop treatment with ZIIHERA, or other medicines you take.

Please see additional Important Safety Information throughout, and full Prescribing Information, including BOXED WARNINGS and Medication Guide.



ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

UNDERSTANDING YOUR TYPE OF CANCER

A DIAGNOSIS LIKE THIS CAN FEEL OVERWHELMING

When you're told you have metastatic or advanced GEA—or gastroesophageal adenocarcinoma—it comes with a lot of new information. It's okay to take it one step at a time. There will be new tests, new decisions, and new words to learn along the way, such as GEA. GEA is a group of cancers that starts in the esophagus, stomach, or the area where the two meet, called the gastroesophageal junction (GEJ).

THE 3 TYPES OF CANCER THAT MAKE UP GEA:



Key Terms

- **GEA:** gastroesophageal adenocarcinoma; the medical name for cancers that start in the esophagus, stomach, or place where they meet
- **Metastatic:** cancer that has spread to a different part of your body than where it first appeared

IMPORTANT SAFETY INFORMATION (CONT'D)

ZIIHERA can cause serious side effects, including:

If you get new or worsening diarrhea, tell your healthcare provider right away and take antidiarrheal medicine as prescribed. Follow all of your healthcare providers instructions to help with your diarrhea.

- **Harm to your unborn baby.** Taking ZIIHERA during pregnancy or within 4 months before pregnancy can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZIIHERA.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with ZIIHERA.
- Use effective birth control (contraception) during treatment with ZIIHERA and for 4 months after the last dose.

Please see additional Important Safety Information throughout, and full Prescribing Information, including BOXED WARNINGS and Medication Guide.



ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

WHAT IS ZIIHERA?

ZIIHERA IS PART OF A TREATMENT PLAN DESIGNED FOR YOUR TYPE OF CANCER

ZIIHERA targets HER2, which is a biomarker on some cancer cells. Too much HER2 can cause cancer to grow. ZIIHERA is a first-line treatment option for your type of cancer, HER2+ advanced GEA.

ZIIHERA attaches to the HER2 biomarker in two different spots on a cancer cell. This “double grip” may slow or stop the cancer from growing and signals to your immune system to help fight your cancer.



The “double-grip” difference of ZIIHERA

It’s like squeezing a lemon with two hands instead of one.
You may get more juice with the double hold.

ZIIHERA is given with chemotherapy. Some people also receive another type of treatment with it called tislelizumab (immunotherapy).

Key Terms

- **Biomarker:** a target in your cancer cells that helps your doctor choose the right treatment for you; short for “biological marker”
- **HER2:** a biomarker that can be found on cancer cells. Too much HER2 can cause cancer to grow. Targeted treatments are used when there is too much HER2.
- **Immunotherapy:** a treatment that helps activate the immune system so your body can fight cancer
- **Targeted treatment:** a therapy built to find and work against cancer cells with that specific biomarker

IMPORTANT SAFETY INFORMATION (CONT'D)

ZIIHERA can cause serious side effects, including:

- **Heart problems** that may affect how well your heart pumps blood.

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

HOW CAN A ZIIHERA TREATMENT PLAN BENEFIT YOU?

START WITH A CHANCE AT A LONGER LIFE



LIVING LONGER THAN WHAT WAS SEEN BEFORE

Many people who received ZIIHERA + tislelizumab (immunotherapy) + chemotherapy **lived more than two years after starting treatment**, the longest results reported in a clinical trial for your cancer^{*†}

KEEPING CANCER FROM GETTING WORSE



MORE TIME WITHOUT CANCER GROWING OR SPREADING

Many people who received a ZIIHERA treatment plan lived **more than 1 year without their cancer getting worse**, the longest results reported in a clinical trial for your cancer^{*†}

^{*}In the largest clinical trial for your type of cancer, 914 adults with previously untreated HER2+ advanced GEA were divided into 3 treatment groups. 302 people received ZIIHERA + tislelizumab (immunotherapy) + chemotherapy. 304 people received ZIIHERA + chemotherapy alone. 308 people received the comparison treatment, trastuzumab + chemotherapy.

[†]Adults who received ZIIHERA + tislelizumab (immunotherapy) + chemotherapy had a median overall survival of 26.4 months vs 19.2 months with the comparison treatment, trastuzumab + chemotherapy. Overall survival data for people with HER2+ (IHC 3+) advanced GEA who received ZIIHERA + chemotherapy was immature at the time of this analysis.

[‡]In the clinical trial, adults with previously untreated HER2+ advanced GEA had a median progression-free survival of 12.4 months with ZIIHERA + tislelizumab (immunotherapy) + chemotherapy vs 8.1 months with the comparison treatment, trastuzumab + chemotherapy. Adults with previously untreated HER2+ (IHC 3+) advanced GEA had a median progression-free survival of 14.2 months with ZIIHERA + chemotherapy vs 7.6 months with trastuzumab + chemotherapy.

Key Terms

- **IHC:** a way to measure and score how much HER2 protein is present on your cancer cells to help choose the best treatment
- **Immunotherapy:** a treatment that may help activate the immune system so your body can fight cancer
- **Median:** the middle number in a set of data arranged from lowest to highest. If a median overall survival is 2 years, it means half of people lived more than 2 years
- **Overall survival:** how long people lived after starting treatment
- **Progression-free survival:** how long people lived without their cancer growing or spreading. This includes dying from any cause as well

IMPORTANT SAFETY INFORMATION (CONT'D)

ZIIHERA can cause serious side effects, including (cont'd):

Your healthcare provider will check your heart function before and during treatment with ZIIHERA.

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

WHAT SHOULD YOU KNOW ABOUT SIDE EFFECTS?

KNOWING WHAT TO EXPECT HELPS YOU PREPARE FOR YOUR TREATMENT

ZIIHERA can cause serious side effects, including:

- **Diarrhea.** Diarrhea during treatment with ZIIHERA can be severe, life threatening, and can lead to death. Diarrhea may cause loss of fluids and body salts (electrolytes). Follow all of your care team's instructions to help with your diarrhea.
- **Harm to an unborn baby.** Taking ZIIHERA during pregnancy or within 4 months before pregnancy can harm your unborn baby.
- **Heart problems** that may affect how well your heart pumps blood.
- **Infusion-related reactions**

More severe or worse side effects occurred more often in people who were 65 years or older who received ZIIHERA + tislelizumab (immunotherapy) + chemotherapy (87%) compared to people younger than 65 years (80%).

Other common side effects when ZIIHERA is given in combination with chemotherapy and tislelizumab include:

- diarrhea
- nausea
- decreased appetite
- low levels of blood potassium
- vomiting
- feeling tired
- numbness, pain, tingling, or burning in your hands or feet
- rash
- infusion-related reactions

Other common side effects when ZIIHERA is given in combination with chemotherapy include:

- diarrhea
- nausea
- vomiting
- numbness, pain, tingling, or burning in your hands or feet
- decreased appetite
- feeling tired
- low levels of blood potassium
- infusion-related reactions
- rash

Tell your care team if you have any side effect that bothers you or that does not go away.

- Your care team may slow down, pause, or stop your treatment with ZIIHERA if you have certain side effects. They will work with you to help manage side effects and treat them when they do happen.



Please see Important Safety Information throughout, and full Prescribing Information, including BOXED WARNINGS and Medication Guide.


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

WHAT SHOULD YOU KNOW ABOUT SIDE EFFECTS?



MANAGING DIARRHEA

With ZIIHERA treatment plans, about **4 out of 5 people** experienced diarrhea in the clinical trial. Less than 5% of people had to stop taking ZIIHERA because of diarrhea. For most people, diarrhea typically happened during the first round of treatment and **got better within 3 weeks.**

- Your care team will instruct you to take loperamide (Imodium®) before you receive ZIIHERA to help manage diarrhea*
- It's important you take this medicine (4 mg) twice daily for at least the first 7 days of your first round of treatment with ZIIHERA, and as directed by your care team afterward
- You may be instructed to drink more fluids while on a ZIIHERA treatment plan, especially if you experience diarrhea
- If you get new or worsening diarrhea, notify your care team right away



Managing side effects starts before your first infusion. Being prepared ahead of time may help support you on your treatment journey with ZIIHERA.

*Imodium is a registered trademark of Kenvue Brands LLC.

IMPORTANT SAFETY INFORMATION (CONT'D)

ZIIHERA can cause serious side effects, including (cont'd):

Tell your healthcare provider right away if you get any of the following signs and symptoms of a heart problem:

- new or worsening shortness of breath
- feeling more tired than usual
- swelling of your ankles or feet
- loss of consciousness
- irregular heartbeat
- sudden weight gain
- dizziness or feeling light-headed

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**


ZIIHERA®
(zanidatamab-hrii)
50mg/ml Injection for IV

HOW WILL YOU RECEIVE ZIIHERA?

ZIIHERA IS GIVEN THROUGH AN IV INFUSION

- Plan for your ZIIHERA infusions to take some time. Your first treatment will likely take the longest
 - You may want to bring a book, download a podcast, or plan to watch a TV show during your infusions
- Treatment will be scheduled every 2 or 3 weeks. Your doctor will decide how many treatments you need and what schedule is right for you
- You will receive ZIIHERA in a clinic or infusion center



Key Terms

- **Infusion:** a method of putting medicine directly into your bloodstream
- **IV:** intravenous, or in your vein

IMPORTANT SAFETY INFORMATION (CONT'D)

ZIIHERA can cause serious side effects, including (cont'd):

- **Infusion-related reactions.** Your healthcare provider will check for side effects during your infusions. Tell your healthcare provider right away if you get any of the following symptoms during or after your infusions of ZIIHERA:
 - shortness of breath or trouble breathing
 - fever
 - chills
 - rash
 - flushing
 - nausea or vomiting
 - dizziness or feeling light-headed
 - chest discomfort

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

HOW WILL YOU RECEIVE ZIIHERA?

KNOWING WHAT TO EXPECT CAN HELP YOU FEEL MORE IN CONTROL

- Your care team will give you medicines 30 to 60 minutes before each ZIIHERA treatment to reduce the risk of infusion related reactions or make them less severe
- Chemotherapy is given with ZIIHERA at the beginning of treatment. Your healthcare provider will decide how much chemotherapy is needed
 - You may also be given tislelizumab (immunotherapy) if your healthcare provider decides it is right for your treatment plan
 - If you miss a dose, call your healthcare provider as soon as possible to reschedule your appointment

Check out the What to Expect Guide at ZIIHERAresources.com for more.



It's important that you take **loperamide (4 mg) twice daily for at least the first 7 days** of your first round of treatment with ZIIHERA, and as directed by your care team afterward.

IMPORTANT SAFETY INFORMATION (CONT'D)

Before receiving ZIIHERA, tell your healthcare provider about all of your medical conditions, including if you:

- have or have had any heart problems.
- are breastfeeding or plan to breastfeed. It is not known if ZIIHERA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you receive treatment with ZIIHERA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Other common side effects when ZIIHERA is given in combination with chemotherapy and tislelizumab-jsgr include:

- | | |
|---------------------------------|--|
| ○ diarrhea | ○ feeling tired |
| ○ nausea | ○ numbness, pain, tingling, or burning in your hands or feet |
| ○ decreased appetite | ○ rash |
| ○ low levels of blood potassium | ○ infusion-related reactions |
| ○ vomiting | |

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

YOU ARE NOT ALONE IN THIS



SUPPORT IS CLOSER THAN YOU MAY THINK

A diagnosis like this can feel isolating. But there are organizations dedicated to people with your type of cancer that offer real support, from online communities to one-on-one help. Reaching out is a great way to learn from others that have been on this journey.

Visit ZIIHERA.com/advocacy-and-support to find information about support organizations.

JazzCares is committed to helping you get access to your ZIIHERA medication.

Visit ZIIHERA.com/jazzcares



IMPORTANT SAFETY INFORMATION (CONT'D)

Other common side effects when ZIIHERA is given in combination with chemotherapy include:

- diarrhea
- nausea
- vomiting
- numbness, pain, tingling, or burning in your hands or feet
- decreased appetite
- feeling tired
- low levels of blood potassium
- infusion-related reactions
- rash

These are not all the possible side effects of ZIIHERA. Call your doctor for medical advice about side effects. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout, and full [Prescribing Information](#), including **BOXED WARNINGS** and [Medication Guide](#).


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

ZIIHERA can cause serious side effects, including:

- **Diarrhea.** Diarrhea during treatment with ZIIHERA can be severe, life threatening, and can lead to death. Diarrhea may cause loss of fluids and body salts (electrolytes). To help prevent or reduce diarrhea during treatment with ZIIHERA, your healthcare provider:
 - will tell you to drink more fluids.
 - start you on an antidiarrheal medicine such as loperamide or other treatment, as needed.
 - may temporarily stop, reduce your dose or permanently stop treatment with ZIIHERA, or other medicines you take.

If you get new or worsening diarrhea, tell your healthcare provider right away and take antidiarrheal medicine as prescribed. Follow all of your healthcare providers instructions to help with your diarrhea.

- **Harm to your unborn baby.** Taking ZIIHERA during pregnancy or within 4 months before pregnancy can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZIIHERA.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with ZIIHERA.
- Use effective birth control (contraception) during treatment with ZIIHERA and for 4 months after the last dose.
- **Heart problems** that may affect how well your heart pumps blood. Your healthcare provider will check your heart function before and during treatment with ZIIHERA. Tell your healthcare provider right away if you get any of the following signs and symptoms of a heart problem:
 - new or worsening shortness of breath
 - irregular heartbeat
 - feeling more tired than usual
 - sudden weight gain
 - swelling of your ankles or feet
 - dizziness or feeling light-headed
 - loss of consciousness
- **Infusion-related reactions.** Your healthcare provider will check for side effects during your infusions. Tell your healthcare provider right away if you get any of the following symptoms during or after your infusions of ZIIHERA:
 - shortness of breath or trouble breathing
 - flushing
 - fever
 - nausea or vomiting
 - chills
 - dizziness or feeling light-headed
 - rash
 - chest discomfort

Please see additional Important Safety Information throughout, and full [Prescribing Information](#), including **BOXED WARNINGS** and [Medication Guide](#).


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

IMPORTANT SAFETY INFORMATION (CONT'D)

IMPORTANT SAFETY INFORMATION

Before receiving ZIIHERA, tell your healthcare provider about all of your medical conditions, including if you:

- have or have had any heart problems.
- are breastfeeding or plan to breastfeed. It is not known if ZIIHERA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you receive treatment with ZIIHERA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Other common side effects when ZIIHERA is given in combination with chemotherapy and tislelizumab-jsgr include:

- diarrhea
- nausea
- decreased appetite
- low levels of blood potassium
- vomiting
- feeling tired
- numbness, pain, tingling, or burning in your hands or feet
- rash
- infusion-related reactions

Other common side effects when ZIIHERA is given in combination with chemotherapy include:

- diarrhea
- nausea
- vomiting
- numbness, pain, tingling, or burning in your hands or feet
- decreased appetite
- feeling tired
- low levels of blood potassium
- infusion-related reactions
- rash

These are not all the possible side effects of ZIIHERA. Call your doctor for medical advice about side effects.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**


ZIIHERA[®]
(zanidatamab-hrii)
50mg/ml Injection for IV

YOU HAVE PLANS.
**AND WE HAVE
SUPPORT.**



Visit ZIIHERA.com/stay-connected
to receive your complimentary Care Package.

IMPORTANT SAFETY INFORMATION

ZIIHERA can cause serious side effects, including:

- **Diarrhea.** Diarrhea during treatment with ZIIHERA can be severe, life threatening, and can lead to death. Diarrhea may cause loss of fluids and body salts (electrolytes). To help prevent or reduce diarrhea during treatment with ZIIHERA, your healthcare provider:
 - will tell you to drink more fluids.
 - start you on an antidiarrheal medicine such as loperamide or other treatment, as needed.
 - may temporarily stop, reduce your dose or permanently stop treatment with ZIIHERA, or other medicines you take.

If you get new or worsening diarrhea, tell your healthcare provider right away and take antidiarrheal medicine as prescribed. Follow all of your healthcare providers instructions to help with your diarrhea.

Please see additional Important Safety Information throughout, and full Prescribing Information, including **BOXED WARNINGS and Medication Guide.**